Dr. Feixiang Wu 吴飞翔
Chief Physician
Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Clinical and basic research on benign and malignant liver and pancreatic tumors, with a focus on diagnosis and comprehensive treatment of primary liver cancer and pancreatic cancer.
Dr. Wu holds an MD and serves as Chief Physician and Doctoral Supervisor at Guangxi Medical University Cancer Hospital. Dr. Wu leads the Liver and Pancreas Ward. Research awards include the 2017 Guangxi Medical Health Technology Promotion Award (First Prize) and two 2018–2019 Guangxi Science and Technology Progress Awards (First Prize). Dr. Wu has led multiple National Natural Science Foundation projects and published over 20 SCI-indexed papers.
Professional roles
- Vice Chair, Biliary and Pancreatic Professional Committee, Guangxi Anti-Cancer Association
- Member, Liver Cancer Professional Committee, Chinese Medical Doctor Association
- Member, China Branch, International Hepato-Pancreato-Biliary Association
- Editorial Board Member, Chinese Journal of Cancer Prevention and Treatment
Name order: in Chinese the family name comes first (Wu Feixiang). Papers usually list the name as Feixiang Wu or Wu F.
Selected publications
25 papers on PubMed matched by name and affiliation; 13 as first or senior author since 2016. Most recent first- or senior-author papers:
- Food Sci Nutr, 2026 (senior author): Lactobacillus murinus Alleviates High Fructose-Induced MASLD by Boosting Arginine Production. PubMed 41710809
- World J Surg Oncol, 2025 (senior author): Safety and efficacy of salvage surgery for unresectable hepatocellular carcinoma after conversion with triple therapy: a systematic review and meta-analysis of data from Chinese patients. PubMed 41331587
- Front Immunol, 2025 (senior author): Predicting recurrence and recurrence-free survival in initially unresectable hepatocellular carcinoma: a novel nomogram for patients undergoing conversion hepatectomy with lenvatinib, PD-1 inhibitor, and interventional therapy. PubMed 40808940
- Front Cell Infect Microbiol, 2025 (senior author): Postoperative hepatitis B virus reactivation and its impact on survival in HBV-related hepatocellular carcinoma patients undergoing conversion therapy with interventional therapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors. PubMed 40746957
- Environ Toxicol, 2024 (senior author): Value of hepatic artery digital subtraction angiography in the detection of small hepatocellular carcinoma lesions. PubMed 39162414
- J Hepatocell Carcinoma, 2024 (senior author): The Role of Timing of Progression and Early Salvage Surgery in Unresectable Hepatocellular Carcinoma Treated with TACE Plus TKIs and PD‑1 Inhibitors. PubMed 39206421
- Int J Nanomedicine, 2024 (senior author): Combined Effects of Anti-PD-L1 and Nanosonodynamic Therapy on HCC Immune Activation in Mice: An Investigation. PubMed 39050875
- BMC Cancer, 2024 (senior author): TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study. PubMed 38862932
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion